Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Alligator Bioscience AB ( (SE:ATORX) ) has provided an announcement.
Alligator Bioscience will present new clinical data from its Phase 1b/2 OPTIMIZE-1 study of the CD40 agonist mitazalimab in combination with standard mFOLFIRINOX chemotherapy in previously untreated metastatic pancreatic ductal adenocarcinoma at the ASCO Gastrointestinal Cancers Symposium 2026 in San Francisco. The final efficacy analyses further characterize the clinical benefit of the combination and support Alligator’s preparations for pivotal development of mitazalimab, potentially strengthening the drug’s profile in a highly challenging cancer indication and reinforcing the company’s positioning in CD40-based immunotherapy as it engages key opinion leaders and advances toward Phase 3.
The most recent analyst rating on (SE:ATORX) stock is a Sell with a SEK0.32 price target. To see the full list of analyst forecasts on Alligator Bioscience AB stock, see the SE:ATORX Stock Forecast page.
More about Alligator Bioscience AB
Alligator Bioscience AB is a Swedish biotechnology company headquartered in Lund and listed on Nasdaq Stockholm, developing clinical-stage, tumor-directed antibody drugs that target the CD40 receptor. Its lead candidate, mitazalimab, is an immuno-oncology therapy designed to prime T cells and reverse tumor immunosuppression, with a particular focus on hard-to-treat cancers such as metastatic pancreatic cancer, and is currently ready for Phase 3 development after promising Phase 2 survival data.
Average Trading Volume: 4,504,905
Technical Sentiment Signal: Sell
Current Market Cap: SEK165.8M
Learn more about ATORX stock on TipRanks’ Stock Analysis page.